Comparative study of the pharmacokinetics widely used lipid-lowering drugs of the statin
Abstract
The comparative pharmacokinetics of commonly used lipid-lowering drugs of the statin was studied by
54 healthy persons. Concentration atorvastatin, the active metabolites of simvastatin and lovastatin in plasma
by HPLC with UV-spectrophotometric detector were determined.
54 healthy persons. Concentration atorvastatin, the active metabolites of simvastatin and lovastatin in plasma
by HPLC with UV-spectrophotometric detector were determined.
About the Authors
А. Сивков
СивковПервый МГМУ им. И.М. Сеченова, Минздравсоцразвития РФ, Москва
Контактана
Russian Federation
Russian Federation
A. S. Sivkov
Russian Federation
References
1. Lennernas H., Fager G. Pharmaco-гия. М: Гэотармед. 2008. dynamics and pharmacokinetics of theКукес В.Г. Метаболизм лекарствен- HMG-CoA reductase inhibitors. Clin.ных средств; клинико-фармакологи- Pharmacokinet. 1997. 32: 403-425.ческие аспекты. М.: Рефарм. 2004.
2. Ayanian J.Z., Fuchs C.S., Stone R.M. 9. Long-Term Intervention with Pravas- tatin in Ischemic Disease (LIPID)Lovastatin and rhabdomyolysis. Ann. Study Group. Prevention of cardiovas-Intern. Med. 1988. 109: 682-683. cular events and death with pravastatinCorsini A., Bellosta S., Baetta R. et in patients with coronary heart diseaseal. New insights into the pharmacody- and a broad range of initial cholesterolnamic and pharmacokinetic properties levels. N. ENGL. J. MED. 1998. 339:of statins. Pharmacol. Ther. 1999. 84: 1349-1357.413-428.
3. Desager L.P., Horsmans Y. Clinical 10. Muck W. Rational assessment of the in- teraction profile of atorvastatin supportspharmacokinetics of the HMG-CoA its low propensity for drug interactions.reductase inhibitors. Clin. Pharmacoki- Drugs, 1998, 56 (Suppl. 1): 15 - 23.net. 1996. 31: 348-341.
4. Hamelin B.A., Turgeon J. Hydrophi- 11. Richter W.O., Jacob B.G., Schwandt P. Interaction between fibre and lovas-licity/lipophilicity: relevance for the 103 Biomedicine № 2, 2012
5. А.С. Сивков tatin. Lancet. 1991. 338: 706.
6. Shepherd J., Cobble S.M., Ford J. et al. Prevention of coronary heart disease with pravastatin in men with hypercho- lesterolemia. N. Engl. J. Med. 1995. 333: 1301-1307.
7. Stern R.H., Gibson D.M., Whit- field L.R. Cimetidine does not alter atorvastatin pharmacokinetics or LDL- cholesterol reduction. Eur. J. Clin. Phar- macol. 1998. 53: 475-478.
8. Wrighton S.A., Vandenbranden M., Ring B.J. The human drug metaboliz- ing cytochromes P450. J. Pharmacoki- net. Biopharm. 1996. 24: 475-489.
Review
For citations:
, Sivkov A.S. Comparative study of the pharmacokinetics widely used lipid-lowering drugs of the statin. Journal Biomed. 2012;1(2):98-104. (In Russ.)
Views:
208
Email this article 
